연구동향 분석
박사

Mechanism of resistance to 17-DMAG, an Hsp90 inhibitor, in lung cancer cell lines with ALK rearrangement : Hsp90 억제제인 17-DMAG 에 대한 ALK 유전자 전위가 있는 폐암 세포주의 내성 발현 기전에 관한 연구

김희정 2015년

논문상세정보
인용/피인용
' Mechanism of resistance to 17-DMAG, an Hsp90 inhibitor, in lung cancer cell lines with ALK rearrangement : Hsp90 억제제인 17-DMAG 에 대한 ALK 유전자 전위가 있는 폐암 세포주의 내성 발현 기전에 관한 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • anaplastic lymphoma kinase
  • heat shock protein 90
  • lung cancer
  • p-glycoprotein
  • resistance
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
603 0

0.0%

' Mechanism of resistance to 17-DMAG, an Hsp90 inhibitor, in lung cancer cell lines with ALK rearrangement : Hsp90 억제제인 17-DMAG 에 대한 ALK 유전자 전위가 있는 폐암 세포주의 내성 발현 기전에 관한 연구' 의 참고문헌

  • Zhang H, Neely L, Lundgren K, et al. BIIB021, asynthetic Hsp90 inhibitor, has broad application againsttumors with acquired multidrug resistance. Int J Cancer2010;126(5):1226-34.
  • Young LC, Campling BG, Cole SP, Deeley RG, GerlachJH. Multidrug resistance proteins MRP3, MRP1, andMRP2 in lung cancer: correlation of protein levels withdrug response and messenger RNA levels. Clin CancerRes 2001;7:1798-804.
  • Yang Y, Zhang Y, Wu Q, et al. Clinical implications ofhigh NQO1 expression in breast cancers. J Exp ClinCancer Res 2013;33:14.
  • Wang M, Hong X, Sun Q, Li R, Yang Z, Chen G.[Establishment of animal model of a human lungadenocarcinoma drug-resistantcell line Anip973/NVB andinvestigation on mechanism of drug resistance]. ZhongguoFei Ai Za Zhi 2012;15:146-51.
  • Taldone T, Gozman A, Maharaj R, Chiosis G. TargetingHsp90: small-molecule inhibitors and their clinicaldevelopment. Curr Opin Pharmacol 2008;8:370-4.
  • Solomon B, Wilner KD, Shaw AT. Current status oftargeted therapy for anaplastic lymphoma kinaserearrangednon-small cell lung cancer. Clin PharmacolTher 2014;95:15-23.
  • Soda M, Choi YL, Enomoto M, et al. Identification of thetransforming EML4-ALK fusion gene in non-small-celllung cancer. Nature 2007;448:561-6.
  • Socinski MA, Goldman J, El-Hariry I, et al. A multicenterphase II study of ganetespib monotherapy in patients withgenotypically defined advanced non-small cell lung cancer.Clin Cancer Res 2013;19:3068-77.
  • Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinicalfeatures and outcome of patients with non-small-cell lungcancer who harbor EML4-ALK. J Clin Oncol2009;27:4247-53.
  • Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versuschemotherapy in advanced ALK-positive lung cancer. NEngl J Med 2013;368:2385-94.
  • Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALKrearrangednon-small-cell lung cancer. N Engl J Med2014;370:1189-97.
  • Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patientswith molecularly defined non-small-cell lung cancer. JClin Oncol 2010;28:4953-60.
  • Sasaki T, Koivunen J, Ogino A, et al. A novel ALKsecondary mutation and EGFR signaling cause resistanceto ALK kinase inhibitors. Cancer Res 2011;71:6051-60.
  • Sang J, Acquaviva J, Friedland JC, et al. Targetedinhibition of the molecular chaperone Hsp90 overcomesALK inhibitor resistance in non-small cell lung cancer.Cancer Discov 2013;3:430-43.
  • Sameer AS, Shah ZA, Syeed N, Rasool R, Afroze D,Siddiqi MA. NAD(P)H:quinone oxidoreductase 1 (NQO1)Pro187Ser polymorphism and colorectal cancerpredisposition in the ethnic Kashmiri population. AsianPac J Cancer Prev 2010;11:209-13.
  • Romermann K, Wanek T, Bankstahl M, et al. (R)-[(11)C]verapamil is selectively transported by murine andhuman P-glycoprotein at the blood-brain barrier, and notby MRP1 and BCRP. Nucl Med Biol 2013;40(7):873-8.
  • Rho JK, Lee H, Park CS, Choi CM, Lee JC. Sensitivedetection of EML4-ALK fusion oncoprotein of lungcancer by in situ proximity ligation assay. Clin Chem LabMed;51:1843-8.
  • Powers MV, Clarke PA, Workman P. Dual targeting ofHSC70 and HSP72 inhibits HSP90 function and inducestumor-specific apoptosis. Cancer Cell 2008;14:250-62.
  • Normant E, Paez G, West KA, et al. The Hsp90 inhibitorIPI-504 rapidly lowers EML4-ALK levels and inducestumor regression in ALK-driven NSCLC models.Oncogene 2011;30:2581-6.
  • Mosse YP, Wood A, Maris JM. Inhibition of ALKsignaling for cancer therapy. Clin Cancer Res2009;15:5609-14.
  • Melguizo C, Prados J, Luque R, et al. Modulation ofMDR1 and MRP3 Gene Expression in Lung Cancer Cellsafter Paclitaxel and Carboplatin Exposure. Int J Mol Sci2012;13:16624-35.
  • McCollum AK, Teneyck CJ, Sauer BM, Toft DO,Erlichman C. Up-regulation of heat shock protein 27induces resistance to 17-allylaminodemethoxygeldanamycinthrough a glutathione-mediatedmechanism. Cancer Res 2006;66:10967-75.
  • Ma Y, Kong J, Yan G, et al. NQO1 overexpression isassociated with poor prognosis in squamous cellcarcinoma of the uterine cervix. BMC Cancer 2014;14:414.
  • Lin L, Qin Y, Jin T, et al. Significance of NQO1overexpression for prognostic evaluation of gastricadenocarcinoma. Exp Mol Pathol 2014;96:200-5.
  • Kwak EL, Bang YJ, Camidge DR, et al. Anaplasticlymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med 2010;363:1693-703.
  • Koll TT, Feis SS, Wright MH, et al. HSP90 inhibitor,DMAG, synergizes with radiation of lung cancer cells byinterfering with base excision and ATM-mediated DNArepair. Mol Cancer Ther 2008;7:1985-92.
  • Kobayashi N, Toyooka S, Soh J, et al. The antiproliferativeeffect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant toEGFR tyrosine kinase inhibitor. Lung Cancer.2012;75:161-6.
  • Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC.Epithelial-mesenchymal transition leads to crizotinibresistance in H2228 lung cancer cells with EML4-ALKtranslocation. Mol Oncol 2013;7:1093-102.
  • Katayama R, Shaw AT, Khan TM, et al. Mechanisms ofacquired crizotinib resistance in ALK-rearranged lungCancers. Sci Transl Med 2012;4:120ra17.
  • Katayama R, Khan TM, Benes C, et al. Therapeuticstrategies to overcome crizotinib resistance in non-smallcell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011;108:7535-40.
  • Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP.Taxol: mechanisms of action and resistance. J Natl CancerInst Monogr 1993;15:55-61.
  • Hollingshead M, Alley M, Burger AM, et al. In vivoantitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycinhydrochloride), a water-soluble geldanamycin derivative.Cancer Chemother Pharmacol 2005;56:115-25.
  • Gaspar N, Sharp SY, Pacey S, et al. Acquired resistance to17-allylamino-17-demethoxygeldanamycin (17-AAG,tanespimycin) in glioblastoma cells. Cancer research2009;69(5):1966-75.
  • Ettinger DS, Akerley W, Borghaei H, et al. Nationalcomprehensive cancer network. Non-small cell lungcancer, version 2.2013. J Natl Compr Canc Netw2013;11:645-53.
  • Erlichman C. Tanespimycin: the opportunities andchallenges of targeting heat shock protein 90. Expertopinion on investigational drugs 2009;18:861-8.
  • Choi YL, Soda M, Yamashita Y, et al. EML4-ALKmutations in lung cancer that confer resistance to ALKinhibitors. N Engl J Med 20108;363:1734-9.
  • Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar KR, Li WD.Lung resistance protein and multidrug resistance protein innon-small cell lung cancer and their clinical significance. JInt Med Res 2011;39:1693-700.
  • Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK,PI3K/MEK, and HSP90 in murine lung adenocarcinomainduced by EML4-ALK fusion oncogene. Cancer Res2010;70:9827-36.
  • Carmichael J, DeGraff WG, Gazdar AF, Minna JD,Mitchell JB. Evaluation of a tetrazolium-basedsemiautomated colorimetric assay: assessment ofradiosensitivity. Cancer research 1987;47(4):943-6.
  • Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition asa therapeutic approach for overcoming multidrugresistance in cancer: current status and future perspectives.Curr Cancer Drug Targets 2013;13:326-46.
  • Benchekroun MN, Schneider E, Safa AR, Townsend AJ,Sinha BK. Mechanisms of resistance to ansamycinantibiotics in human breast cancer cell lines. MolPharmacol 1994;46:677-84.
  • Achira M, Suzuki H, Ito K, Sugiyama Y. Comparativestudies to determine the selective inhibitors for Pglycoproteinand cytochrome P4503A4. AAPS PharmSci1999;1:E18.